Free Trial
→ I'm handing you this stock today (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$85.60
+0.7%		$93.08
$79.52
▼
$124.00
$21.51B1.281.04 million shs844,647 shs
Moderna, Inc. stock logo
MRNA
Moderna
$223.37
-3.4%		$201.67
$22.28
▼
$280.80
$93.61B1.1615.52 million shs8.04 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
+0.66%-2.18%-3.45%-8.05%-23.30%
Moderna, Inc. stock logo
MRNA
Moderna
-3.45%-12.12%-1.29%+252.76%+736.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$85.60
+0.7%		$93.08
$79.52
▼
$124.00
$21.51B1.281.04 million shs844,647 shs
Moderna, Inc. stock logo
MRNA
Moderna
$223.37
-3.4%		$201.67
$22.28
▼
$280.80
$93.61B1.1615.52 million shs8.04 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
+0.66%-2.18%-3.45%-8.05%-23.30%
Moderna, Inc. stock logo
MRNA
Moderna
-3.45%-12.12%-1.29%+252.76%+736.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.68
Moderate Buy$122.2742.83% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$113.75-49.08% Downside

Current Analyst Ratings Breakdown

Latest MRNA and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$230.00 ➝ $305.00
11/9/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$130.00 ➝ $110.00
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$137.00 ➝ $195.00
11/4/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
11/4/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$135.00 ➝ $125.00
11/4/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$114.00 ➝ $106.00
11/4/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$140.00 ➝ $125.00
10/27/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeOutperform ➝ Market Perform
10/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$167.00 ➝ $230.00
10/23/2026
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell
10/21/2026
Moderna, Inc. stock logo
MRNA
Moderna
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
(Data available from 11/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B6.67$1.34 per share63.69$80.61 per share1.06
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B46.49N/AN/A$16.90 per share13.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$6.85N/AN/AN/A-61.39%-4.51%-3.96%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.10N/AN/AN/A-110.46%-25.79%-15.85%N/A

Latest MRNA and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$1.10$0.38+$1.48$0.38$890.25 million$1.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.55
8.52
Moderna, Inc. stock logo
MRNA
Moderna
0.52
3.62
3.47

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700404.62 million360.92 millionOptionable

Recent News About These Companies

Moderna to relocate UK commercial headquarters to TRIBECA in King’s Cross, London
November 14 at 8:24 AM  |  pharmabiz.comP
Aberdeen Group plc Buys 1,039,311 Shares of Moderna, Inc. $MRNA
November 14 at 3:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-aberdeen-group-plc-buys-1039311-shares-of-moderna-inc-mrna-2026-11-14/
Moderna, Inc. (MRNA) - What Are Analysts Saying About This Stock?
November 14 at 2:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31197344
Moderna, Inc. (NASDAQ:MRNA) Stock Has Average Target Price of $113.75
November 14 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-moderna-inc-nasdaq-mrna-stock-has-average-target-price-of-11375-2026-11-14/
The Single Most Important Metric For Moderna Stock
November 13 at 7:19 PM  |  trefis.comT
Moderna (NASDAQ:MRNA) Stock Price Down 3.4% - Time to Sell?
November 13 at 5:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-moderna-nasdaq-mrna-stock-price-down-34-time-to-sell-2026-11-13/
Moderna, Inc. (MRNA) Analyst/Investor Day - Slideshow
November 13 at 3:35 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4968001-moderna-inc-mrna-analyst-investor-day-slideshow
Moderna phase 3 mRNA therapy result vs BioNTech's oncology pipeline
November 13 at 2:18 PM  |  msn.comhttps://www.msn.com/en-us/money/other/moderna-phase-3-mrna-therapy-result-vs-biontech-s-oncology-pipeline/vi-AA2e0AwT
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
November 13 at 2:18 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-issues-cost-outlook-amid-134700970.html
Promising Biotech Stocks To Consider - November 13th
November 13 at 12:13 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-promising-biotech-stocks-to-consider-november-13th-2026-11-13/
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
November 13 at 10:51 AM  |  zacks.comhttps://www.zacks.com/stock/news/3029512/moderna-issues-cost-outlook-amid-revenue-uncertainty-stock-falls?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-3029512
Letko Brosseau & Associates Inc. Sells 551,496 Shares of Moderna, Inc. $MRNA
November 13 at 6:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-letko-brosseau-associates-inc-sells-551496-shares-of-moderna-inc-mrna-2026-11-13/
Brookline Capital Markets Forecasts Moderna FY2026 Earnings
November 13 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31194885
Moderna Sinks 7% as Analyst Day Cancer Push Brings “$4 Billion in Cash Costs in 2027”
November 12 at 5:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-sinks-7-analyst-day-193806051.html
The Next Chapter of mRNA
November 12 at 5:27 PM  |  time.comT
Why Is Moderna (MRNA) Joining A Global Benchmark And Publishing New Vaccine Data?
November 12 at 5:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-moderna-mrna-joining-global-191002480.html
Moderna (NASDAQ:MRNA) Stock Falls 7% - Here's Why
November 12 at 5:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-moderna-nasdaq-mrna-stock-falls-7-heres-why-2026-11-12/
Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
November 12 at 5:13 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-moderna-targets-2027-cancer-therapy-launch-raises-2026-revenue-growth-outlook-2026-11-12/
MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
November 12 at 1:56 PM  |  zacks.comhttps://www.zacks.com/stock/news/3028961/mrna-stock-up-3-since-q3-earnings-release-how-to-play-the-stock?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-3028961
Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day
November 12 at 12:26 PM  |  pharmexec.comP
Moderna Raises 2026 Revenue Growth Forecast to 15%–25% and Reports Progress in Cancer Vaccine Development
November 12 at 12:26 PM  |  investorshub.advfn.comhttps://investorshub.advfn.com/market-news/article/39899/moderna-raises-2026-revenue-growth-forecast-to-15-25-and-reports-progress-in-cancer-vaccine-development

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
White Tesla sports car parked at a launch site with rocket boosters visible against a sunset sky.
Tesla's Roadster Reveal Hints at 2 Much Bigger Moves
By Sam Quirke | October 19, 2026
Salesforce cloud logo in a futuristic tech setting, highlighting CRM enterprise software and AI platform growth.
Salesforce Fuels AI Engine With $5.66B Braze Buyout
By Jeffrey Neal Johnson | October 21, 2026
Industrial energy facility with cooling units, piping systems, and a large turbine beside flowing water.
These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
By Chris Markoch | October 18, 2026
Lemonade logo over a house graphic with icons for home, renters, car, and pet insurance, a dog and cat in the yard.
Lemonade's Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
By Thomas Hughes | November 8, 2026
Vaccine vial and syringe on a lab surface with DNA strands and virus particle illustrations in the background.
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
By Chris Markoch | October 27, 2026
BioNTech stock logo

BioNTech NASDAQ:BNTX

$85.60 +0.56 (+0.66%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$85.18 -0.42 (-0.50%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna stock logo

Moderna NASDAQ:MRNA

$223.37 -7.98 (-3.45%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$217.50 -5.87 (-2.63%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas